Tumor-Derived Extracellular Vesicles Promote Activation of Carcinoma-Associated Fibroblasts and Facilitate Invasion and Metastasis of Ovarian Cancer by Carrying miR-630.
KLF6
NF-κB pathway
carcinoma-associated fibroblasts
extracellular vesicles
microRNA-630
ovarian cancer
tumor microenvironment
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2021
2021
Historique:
received:
12
01
2021
accepted:
25
05
2021
entrez:
19
7
2021
pubmed:
20
7
2021
medline:
20
7
2021
Statut:
epublish
Résumé
Ovarian cancer (OC) is a lethal gynecological malignancy. Extracellular vesicles (EVs) are crucial media in cell-to-cell communication by carrying microRNAs (miRs). The current study aims to investigate the underlying mechanism of miR-630 carried by OC cell-derived EVs in regard to invasion and metastasis of OC cells. miRs related to OC metastasis were searched and screened. The expression patterns of screened miRs in human normal fibroblasts (NFs) and carcinoma-associated fibroblasts (CAFs) were detected using RT-qPCR. miR-630 related to OC metastasis and CAFs activation was analyzed further. The levels of FAP and α-SMA were detected using Western blotting and immunofluorescence. The migration of NFs was measured using Transwell assay. OC cell-derived EVs were isolated and identified. Uptake of EVs by NFs was observed using immunofluorescence staining. The culture supernatant of NFs was collected and used to culture the low metastasis cell line OVCAR8. The migration and invasion of OC cells and epithelial mesenchymal transition (EMT) were measured. Moreover, a xenograft model was established by injecting OVCAR8 cells of different groups into nude mice. Lastly, the effect of EV-pretreated NFs on invasion and metastasis of OC cells was observed
Identifiants
pubmed: 34277601
doi: 10.3389/fcell.2021.652322
pmc: PMC8277948
doi:
Types de publication
Journal Article
Langues
eng
Pagination
652322Informations de copyright
Copyright © 2021 Cui, Wang and Xie.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancer Biol Ther. 2018 Aug 3;19(8):722-734
pubmed: 29580188
Cancers (Basel). 2017 May 24;9(6):
pubmed: 28538690
Pharmacol Res. 2020 Sep;159:105041
pubmed: 32580030
APL Bioeng. 2018 Jun 07;2(3):031701
pubmed: 31069311
Oncogene. 2006 Sep 28;25(44):6026-31
pubmed: 16702959
Cell Oncol (Dordr). 2020 Aug;43(4):515-538
pubmed: 32418122
Cancer Res. 2005 Jul 15;65(14):5991-5; discussion 5995
pubmed: 16024595
Int J Mol Sci. 2020 Sep 25;21(19):
pubmed: 32993038
Cancers (Basel). 2019 Dec 24;12(1):
pubmed: 31878245
Cell Signal. 2018 May;45:122-131
pubmed: 29374601
Biochimie. 2019 Dec;167:12-24
pubmed: 31493469
Cancer Metastasis Rev. 2018 Dec;37(4):577-597
pubmed: 30465162
Int J Environ Res Public Health. 2019 Apr 29;16(9):
pubmed: 31035447
Genet Mol Res. 2015 Jul 31;14(3):8766-77
pubmed: 26345808
Int J Mol Sci. 2019 Oct 07;20(19):
pubmed: 31591367
Mol Cancer. 2019 Aug 13;18(1):124
pubmed: 31409361
Cell Immunol. 2019 Sep;343:103729
pubmed: 29397066
Elife. 2017 Oct 31;6:
pubmed: 29087294
J Cell Biochem. 2019 Aug;120(8):13187-13201
pubmed: 30957275
Oncogene. 2016 Aug 18;35(33):4312-20
pubmed: 26725326
Mol Cancer. 2019 Mar 30;18(1):70
pubmed: 30927908
Eur Rev Med Pharmacol Sci. 2019 Jun;23(11):4650-4655
pubmed: 31210290
Exp Mol Pathol. 2020 Apr;113:104381
pubmed: 31954715
Front Oncol. 2019 May 03;9:356
pubmed: 31131261
J Cell Mol Med. 2019 Jun;23(6):4338-4348
pubmed: 30983127
Nat Commun. 2017 Mar 06;8:14470
pubmed: 28262727
R Soc Open Sci. 2018 Dec 5;5(12):181006
pubmed: 30662724
Int J Mol Sci. 2020 Aug 21;21(17):
pubmed: 32825667
Mt Sinai J Med. 2009 Dec;76(6):557-66
pubmed: 20014424
Breast. 2015 Oct;24(5):532-8
pubmed: 26210685
J Exp Clin Cancer Res. 2019 Jun 24;38(1):274
pubmed: 31234944
Braz J Med Biol Res. 2020;53(6):e8885
pubmed: 32401925
J Ovarian Res. 2019 Oct 27;12(1):101
pubmed: 31656201
Int J Clin Oncol. 2016 Jun;21(3):435-46
pubmed: 27142770
J Cell Physiol. 2018 May;233(5):3846-3854
pubmed: 28703277
Int J Mol Sci. 2019 Feb 22;20(4):
pubmed: 30813239
Biochem Biophys Res Commun. 2019 Jun 30;514(3):933-939
pubmed: 31088682
PLoS One. 2013 May 10;8(5):e61015
pubmed: 23675407
Mol Oncol. 2018 Nov;12(11):1935-1948
pubmed: 30107086
Eur Rev Med Pharmacol Sci. 2017 Oct;21(20):4542-4547
pubmed: 29131262
Mol Carcinog. 2016 Jul;55(7):1127-37
pubmed: 26153894
Mol Cancer. 2017 Aug 29;16(1):148
pubmed: 28851377
Cell Tissue Res. 2016 Sep;365(3):607-19
pubmed: 27474009
Eur Rev Med Pharmacol Sci. 2019 Jul;23(13):5603-5610
pubmed: 31298312
Front Cell Dev Biol. 2020 Aug 11;8:758
pubmed: 32850861
Toxicol Lett. 2018 Sep 15;294:44-50
pubmed: 29753068
Clin Cancer Res. 2006 Jun 15;12(12):3730-9
pubmed: 16778100
Eur J Cancer Prev. 2018 Jan;27(1):20-26
pubmed: 29084019
Genes Dis. 2019 Oct 03;7(2):172-184
pubmed: 32215287
Elife. 2015 Aug 12;4:
pubmed: 26267216